Literature DB >> 7636277

Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease.

M A Mendall1, D Carrington, D Strachan, P Patel, N Molineaux, J Levi, T Toosey, A J Camm, T C Northfield.   

Abstract

BACKGROUND: Two studies have suggested that seropositivity for Chlamydia pneumoniae (C. pneumoniae) is a risk factor for coronary heart disease (CHD) but the association remains tenuous. Further data is required in other populations to consolidate this observation. AIMS: Initially to determine descriptive risk factors for C. pneumoniae seropositivity in a general population sample and subsequently to examine the relation of seropositivity for this organism to CHD for the first time in a British population.
SETTING: A single general practice health screening clinic and a cardiology clinic involving patients predominantly residing in south London and Surrey.
SUBJECTS: 210 consecutive caucasian men (62%) and women (38%) aged 18-79 including 67 men aged 45-65. This latter group acting as controls were then also compared with 103 consecutive males aged 45-65 with angiographically confirmed coronary heart disease.
METHODS: A questionnaire was administered by a research nurse and serum was analysed for IgG and IgA against C. pneumoniae and other Chlamydiae by a microimmunofluorescence test. Serum was said to be low positive at a specific IgG antibody titre of 16-32, and high positive if 64 or greater.
RESULTS: Amongst the general practice health screening clinic population 14 subjects (7%) were excluded due to possible cross-reactivity with other Chlamydia species (predominantly C. trachomatis). Of the remaining 196 subjects, 13 (6%) had high positive C. pneumoniae IgG titres, 68 (35%) had low titres and 125 had no detectable antibody. After adjustment for sex, age, smoking history, social class and family size only one risk factor for high positive titres in this group was identified, which was the number of children currently living in the home (OR 2.29 (1.09-4.80), P = 0.03). No factors were significantly related to low titres. 22/100 (22%) cases with coronary heart disease and 3/64 (4.7%) of controls had high positive IgG titres for C. pneumoniae. Similarly 21% of cases and 9.4% of controls had positive C. pneumoniae specific IgA serology. 45% of cases and 44% of controls had low C. pneumoniae IgG titres. The association of CHD with a C. pneumoniae IgG titre of 64 or above was independent of all risk factors (OR 7.4 (1.7-33.1), P < 0.01).
CONCLUSION: Serological evidence of C. pneumoniae infection is common amongst healthy British subjects. Smoking and social class are not important confounding variables in this study. Reinfection from contact with infected children in the home may be important in inducing higher titres in some subjects. These higher titres are more prevalent in subjects with coronary heart disease in the U.K. as reported in Finland and the U.S.A., and provide further evidence that C. pneumoniae may be important in the pathogenesis of this condition in these populations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7636277     DOI: 10.1016/s0163-4453(95)80006-9

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  28 in total

1.  Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the caerphilly prospective heart disease study.

Authors:  D P Strachan; D Carrington; M A Mendall; L Ballam; J Morris; B K Butland; P M Sweetnam; P C Elwood
Journal:  BMJ       Date:  1999-04-17

2.  Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis.

Authors:  L A Jackson; L A Campbell; R A Schmidt; C C Kuo; A L Cappuccio; M J Lee; J T Grayston
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

3.  Detection and differentiation of chlamydiae by fluorescence in situ hybridization.

Authors:  Sven Poppert; Andreas Essig; Reinhard Marre; Michael Wagner; Matthias Horn
Journal:  Appl Environ Microbiol       Date:  2002-08       Impact factor: 4.792

4.  Pathohistological changes in diffuse coronary atherosclerosis and chronic infection caused by Chlamydia pneumonia.

Authors:  Mateja Legan; Olga Vraspir-Porenta; Karja Kese; Ruda Zorc-Plesković; Marjeta Zorc
Journal:  Bosn J Basic Med Sci       Date:  2004-02       Impact factor: 3.363

5.  Chlamydia pneumoniae serology: importance of methodology in patients with coronary heart disease and healthy individuals.

Authors:  A Schumacher; A B Lerkerød; I Seljeflot; L Sommervoll; I Holme; J E Otterstad; H Arnesen
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

6.  Comparison of throat swabs with sputum specimens for the detection of Chlamydia pneumoniae antigen by direct immunofluorescence.

Authors:  P Garnett; O Brogan; C Lafong; C Fox
Journal:  J Clin Pathol       Date:  1998-04       Impact factor: 3.411

7.  Atherosclerosis due to chronic arteritis caused by Chlamydia pneumoniae: a tentative hypothesis.

Authors:  W Stille; R Dittmann; G Just-Nübling
Journal:  Infection       Date:  1997 Sep-Oct       Impact factor: 3.553

8.  The relation between Chlamydia pneumoniae and atherosclerosis.

Authors:  S Gupta; E W Leatham
Journal:  Heart       Date:  1997-01       Impact factor: 5.994

9.  Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors.

Authors:  P Patel; M A Mendall; D Carrington; D P Strachan; E Leatham; N Molineaux; J Levy; C Blakeston; C A Seymour; A J Camm
Journal:  BMJ       Date:  1995-09-16

10.  Persistent Chlamydia Pneumoniae serology is related to decline in lung function in women but not in men. Effect of persistent Chlamydia pneumoniae infection on lung function.

Authors:  Thorarinn Gislason; Vilmundur Guðdnason; Bryndis Benediktsdottir; Isleifur Olafsson; Thor Aspelund; Bjarni Thjodleifsson; Christer Janson
Journal:  BMC Pulm Med       Date:  2010-08-25       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.